These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 11668591

  • 1. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
    Robinson S, Krentz L, Moore C, Meshul CK.
    Synapse; 2001 Oct; 42(1):54-61. PubMed ID: 11668591
    [Abstract] [Full Text] [Related]

  • 2. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
    Meshul CK, Allen C.
    Synapse; 2000 May; 36(2):129-42. PubMed ID: 10767060
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway.
    Meshul CK, Cogen JP, Cheng HW, Moore C, Krentz L, McNeill TH.
    Exp Neurol; 2000 Sep; 165(1):191-206. PubMed ID: 10964498
    [Abstract] [Full Text] [Related]

  • 6. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G, Abarca J, Bustos V, Riquelme E, Noriega V, Moya C, Campusano J.
    J Neurosci Res; 2009 Aug 01; 87(10):2308-18. PubMed ID: 19326433
    [Abstract] [Full Text] [Related]

  • 7. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Aug 01; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 8. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity.
    Meshul CK, Tan SE.
    Synapse; 1994 Nov 01; 18(3):205-17. PubMed ID: 7855733
    [Abstract] [Full Text] [Related]

  • 9. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T.
    Synapse; 1997 Aug 01; 26(4):381-91. PubMed ID: 9215597
    [Abstract] [Full Text] [Related]

  • 10. Role of NMDA and AMPA glutamate receptors in the induction and the expression of dopamine-mediated sensitization in 6-hydroxydopamine-lesioned rats.
    Pollack AE, St Martin JL, MacPherson AT.
    Synapse; 2005 Apr 01; 56(1):45-53. PubMed ID: 15700284
    [Abstract] [Full Text] [Related]

  • 11. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ, Marshall JF.
    Synapse; 2000 Jun 01; 36(3):194-204. PubMed ID: 10819899
    [Abstract] [Full Text] [Related]

  • 12. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
    Zeevalk GD, Manzino L, Sonsalla PK.
    Exp Neurol; 2000 Feb 01; 161(2):638-46. PubMed ID: 10686083
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
    Lavoute C, Weiss M, Rostain JC.
    Exp Neurol; 2008 Jul 01; 212(1):63-70. PubMed ID: 18452916
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway.
    Abarca J, Bustos G.
    Neurochem Int; 1999 Jul 01; 35(1):19-33. PubMed ID: 10403427
    [Abstract] [Full Text] [Related]

  • 16. Regulation of cholecystokinin mRNA content in rat striatum: a glutamatergic hypothesis.
    Ding XZ, Mocchetti I.
    J Pharmacol Exp Ther; 1992 Oct 01; 263(1):368-73. PubMed ID: 1403798
    [Abstract] [Full Text] [Related]

  • 17. Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
    Ferraro L, O'Connor WT, Beggiato S, Tomasini MC, Fuxe K, Tanganelli S, Antonelli T.
    Eur J Neurosci; 2012 Jan 01; 35(2):207-20. PubMed ID: 22211865
    [Abstract] [Full Text] [Related]

  • 18. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
    Campbell BM, Kreipke CW, Walker PD.
    Neuroscience; 2006 Jan 01; 137(2):505-17. PubMed ID: 16289829
    [Abstract] [Full Text] [Related]

  • 19. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A, Bentea E, Aourz N, Ampe B, De Deurwaerdère P, Van Eeckhaut A, Massie A, Sarre S, Smolders I, Michotte Y.
    Neuropharmacology; 2014 Oct 01; 85():198-205. PubMed ID: 24863042
    [Abstract] [Full Text] [Related]

  • 20. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV, Groenewegen HJ, Voorn P.
    Synapse; 2002 Jan 01; 43(1):1-11. PubMed ID: 11746728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.